Your browser doesn't support javascript.
loading
Evaluation of triage strategies for high-risk human papillomavirus-positive women in cervical cancer screening: A multicenter randomized controlled trial in different resource settings in China.
Dang, Le; Kong, Linghua; Zhao, Yuqian; Dai, Yi; Ma, Li; Wei, Lihui; Zhang, Shulan; Liu, Jihong; Xi, Mingrong; Chen, Long; Duan, Xianzhi; Xiao, Qing; Abulizi, Guzhalinuer; Zhang, Guonan; Hong, Ying; Zhou, Qi; Xie, Xing; Li, Li; Niyazi, Mayinuer; Zhang, Zhifen; Tuo, Jiyu; Ding, Yiling; Qiao, Youlin; Lang, Jinghe.
Afiliação
  • Dang L; Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100730, China.
  • Kong L; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Zhao Y; Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100730, China.
  • Dai Y; Center for Cancer Prevention Research, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
  • Ma L; Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100730, China.
  • Wei L; Department of Epidemiology, Dalian Medical University, Dalian 116044, China.
  • Zhang S; Department Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
  • Liu J; Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110004, China.
  • Xi M; Department of Gynecology and Obstetrics, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Chen L; Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
  • Duan X; Department of Gynecology and Obstetrics, Zhejiang Xiaoshan Hospital Affiliated to Hangzhou Normal University, Chinese Academy of Medical Sciences/Zhejiang Xiaoshan Hospital Affiliated to Hangzhou Normal University, Hangzhou 310000, China.
  • Xiao Q; Department of Obstetrics and Gynecology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
  • Abulizi G; Department of Gynecology and Obstetrics, the Eight Affiliated Hospital Sun Yat-sen University, Shenzhen 518000, China.
  • Zhang G; 5th Department of Gynecology, the Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830011, China.
  • Hong Y; Department of Gynecologic Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China.
  • Zhou Q; Department of Gynecology and Obstetrics, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
  • Xie X; Department of Gynecological Oncology, Chongqing University Cancer Hospital/Chongqing Cancer Hospital, Chongqing 400030, China.
  • Li L; Department of Gynecologic Oncology, Women's Hospital, School of Medicine Zhejiang University, Hangzhou 310006, China.
  • Niyazi M; Department of Gynecology and Obstetrics, Tumor Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China.
  • Zhang Z; Department of Gynecology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, China.
  • Tuo J; Department of Gynecology, Hangzhou Women's Hospital, Hangzhou 310016, China.
  • Ding Y; Department of Gynecology and Obstetrics, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China.
  • Qiao Y; Department of Gynecology and Obstetrics, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
  • Lang J; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China.
Chin J Cancer Res ; 34(5): 496-509, 2022 Oct 30.
Article em En | MEDLINE | ID: mdl-36398123
ABSTRACT

Objective:

We aimed to evaluate the effectiveness of different triage strategies for high-risk human papillomavirus (hrHPV)-positive women in primary healthcare settings in China.

Methods:

This study was undertaken in 11 rural and 9 urban sites. Women aged 35-64 years old were enrolled. HrHPV-positive women were randomly allocated to liquid-based cytology (LBC), visual inspection with acetic acid and Lugol's iodine (VIA/VILI) (rural only) triage, or directly referred to colposcopy (direct COLP). At 24 months, hrHPV testing, LBC and VIA/VILI were conducted for combined screening.

Results:

In rural sites, 1,949 hrHPV-positive women were analyzed. A total of 852, 218 and 480 women were randomly assigned to direct COLP, LBC and VIA/VILI. At baseline, colposcopy referral rates of LBC or VIA/VILI triage could be reduced by 70%-80%. LBC (n=3 and n=7) or VIA/VILI (n=8 and n=26) could significantly decrease the number of colposcopies needed to detect one cervical intraepithelial neoplasia (CIN) 2 or worse and CIN3+ compared with direct COLP (n=14 and n=23). For the 24-month cumulative detection rate of CIN2+, VIA/VILI triage was 0.50-fold compared with LBC triage and 0.46-fold with the direct COLP. When stratified by age, baseline LBC triage+ performed best (P<0.001), peaking among women aged 35-44 years (Ptrend=0.002). In urban sites, 1,728 women were hrHPV genotyping test positive. A total of 408, 571 and 568 women were randomly assigned to direct COLP for HPV16/18+, direct COLP for other hrHPV subtypes+, and LBC triage for other hrHPV subtypes+. LBC (n=12 and n=31) significantly decreased the number of colposcopies needed to detect one CIN2+ and CIN3+ compared with direct COLP (n=14 and n=44). HPV16/18+ increased the 24-month cumulative detection rate of CIN2+ (17.89%, P<0.001).

Conclusions:

LBC triage for hrHPV-positive women in rural settings and direct COLP for HPV16/18+ women and LBC triage for other hrHPV subtype+ women in urban settings might be feasible strategies.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Chin J Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Chin J Cancer Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China